Edition:
United States

AstraZeneca PLC (AZN)

AZN on New York Consolidated

25.89USD
2 Dec 2016
Change (% chg)

$0.08 (+0.31%)
Prev Close
$25.81
Open
$25.94
Day's High
$26.11
Day's Low
$25.86
Volume
8,836,805
Avg. Vol
6,179,773
52-wk High
$35.04
52-wk Low
$25.76

Summary

Name Age Since Current Position

Leif Johansson

65 2012 Independent Non-Executive Chairman of the Board

Pascal Soriot

57 2012 Executive Director and Chief Executive Officer

Marc Dunoyer

63 2013 Executive Director, Chief Financial Officer

Fiona Cicconi

2014 Executive Vice-President, Human Resources

Sean Bohen

2015 Chief Medical Officer, Executive Vice President - Global Medicines Development

Pam Cheng

45 2015 Executive Vice President - Operations and Information Technology

Ruud Dobber

2013 Executive Vice President, Europe

Paul Hudson

2013 President, AstraZeneca, US and Executive Vice-President, North America

Bahija Jallal

2013 Executive Vice President, MedImmune

Mark Mallon

2013 Executive Vice President, International

Luke Miels

2014 Executive Vice-President, Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs

Menelas Pangalos

2013 Executive Vice President - Innovative Medicines and Early Development

Katarina Ageborg

2011 Chief Compliance Officer

Jeffrey Pott

2009 General Counsel

Adrian Kemp

2009 Company Secretary

Tim Jackson-Smith

2015 Non-Executive Director

Marcus Wallenberg

60 1999 Non-Executive Director

Genevieve Berger

61 2012 Non-Executive Independent Director

Bruce Burlington

67 2010 Non-Executive Independent Director

Ann Cairns

58 2014 Non-Executive Independent Director

Graham Chipchase

52 2012 Non-Executive Independent Director

Jean-Philippe Courtois

55 2008 Non-Executive Independent Director

Rudolph Markham

70 2015 Senior Non-Executive Independent Director

Shriti Vadera

54 2011 Non-Executive Independent Director

Thomas Larsen

2014 IR Contact Officer

Biographies

Name Description

Leif Johansson

Mr. Leif Johansson is Independent Non-Executive Chairman of the Board of AstraZeneca Plc. Elected as a Director in April 26, 2012 and became Non-Executive Chairman of the Board on June 1, 2012. Leif Johansson is also the Chairman of global telecommunications company, LM Ericsson, a position he has held since April 2011. From 1997 until 2011, he was Chief Executive of AB Volvo, one of the world’s manufacturers of trucks, buses, construction equipment, drive systems and aerospace components. He spent a part of his early career at AB Electrolux, latterly as Chief Executive from 1994 to 1997. He was a Non-Executive Director of BMS from 1998 to September 2011, serving on the board’s audit committee and compensation and management development committee. He is Chairman of the European Round Table of Industrialists and the International Advisory Board of the Nobel Foundation. He holds board positions at Svenska Cellulosa Aktiebolaget SCA and Ecolean AB. He holds an MSc in engineering from Chalmers University of Technology, Gothenburg, and has been a member of the Royal Swedish Academy of Engineering Sciences since 1994. He became Chairman of the Academy in 2012.

Pascal Soriot

Mr. Pascal Soriot is Executive Director and Chief Executive Officer of AstraZeneca PLC. Pascal was appointed as a Director and CEO in October 2012. From 2010 to September 2012, he served as Chief Operating Officer of Roche AG’s pharmaceuticals division. Prior to that, he was CEO of Genentech, a biologics business, and led its successful merger with Roche. He joined the pharmaceutical industry in 1986 and has worked in senior management roles throughout the world in a number of major companies. He brings to AstraZeneca a significant breadth of experience in both established and emerging markets, strength of strategic thinking, a successful track record of managing change and putting strategy into operation, and the ability to lead a diverse organisation, having lived in Australia, Japan, the US and Europe. He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from HEC, Paris.

Marc Dunoyer

Mr. Marc Dunoyer is Executive Director, Chief Financial Officer of AstraZeneca PLC. His career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GlaxoSmithKline (GSK), has given him extensive industry experience, including finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganisation; and business development. Marc qualified as an accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, GPPS from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK Japan. He holds an MBA from HEC, Paris and a Bachelor of Law degree from Paris University.

Fiona Cicconi

Ms. Fiona Cicconi is Executive Vice-President, Human Resources of the company. She joined AstraZeneca in September 2014 as Executive Vice-President, Human Resources. She started her career at General Electric where she held various human resources roles within the Oil & Gas business, which included experience in major global acquisitions and driving change. Subsequently, Fiona spent a number of years at Cisco, before joining Roche in 2006 where she was most recently responsible for global human resources for Pharma Technical Operations where her primary focus was to build one culture between Roche and Genentech and identify and develop a sustainable supply of leadership and talent from within the organisation.

Sean Bohen

Dr. Sean Bohen M.D., Ph.D. has been appointed as Chief Medical Officer, Executive Vice President - Global Medicines Development of the Company, effective 15 September 2015. Dr. Bohen joins AstraZeneca from Genentech where he was most recently Senior Vice President of Early Development. He oversaw preclinical and clinical development programmes across all therapy areas, including oncology, respiratory and autoimmune diseases, to deliver trial-ready drug candidates to late-stage development. Before this, he held a number of positions in early and late-stage development, playing a key role in the growth and progress of the Genentech/Roche portfolio. Dr. Bohen was instrumental in bringing a large number of new medicines to patients, in particular for cancer, and led activities to incorporate diagnostics into clinical programmes. Prior to joining Genentech, Dr. Bohen was a Clinical Instructor in Oncology at Stanford University School of Medicine, a research associate at the Howard Hughes Medical Institute and a postdoctoral fellow at the National Cancer Institute. He is a graduate of the University of Wisconsin-Madison and later earned his doctorate in biochemistry and his medical degree at the University of California, San Francisco.

Pam Cheng

Ms. Pam Cheng is the Executive Vice President - Operations and Information Technology of the Company. Pam joined AstraZeneca in June 2015 after having spent 14 years in Global Manufacturing and Supply Chain roles at Merck/MSD. Pam was the Head of Global Supply Chain Management & Logistics for Merck from 2006 to 2011 and led the transformation of Merck supply chains across the global supply network. More recently, Pam was President of MSD China, responsible for MSD’s entire business in China. Prior to joining Merck, Pam held various engineering and project management positions at Universal Oil Products, Union Carbide Corporation and GAF Chemicals. Pam holds Bachelor’s and Master’s degrees in chemical engineering from Stevens Institute of Technology in New Jersey and an MBA in marketing from Pace University in New York.

Ruud Dobber

Mr. Ruud Dobber is the Executive Vice President, Europe of AstraZeneca PLC., He was appointed Executive Vice-President, Europe in January 2013 and leads AstraZeneca’s commercial operations in Europe. In this capacity, Ruud is responsible for sales, marketing and commercial operations across AstraZeneca’s businesses in the 28 EU member states. He served as Interim Executive Vice-President, GPPS from December 2013 until May 2014. Ruud joined AstraZeneca in 1997 and has held various senior commercial roles, including Regional Vice-President of AstraZeneca’s European, Middle East and African division and Regional Vice-President for the Asia Pacific region. Since 2012, Ruud has been an Executive Committee Member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). In 2011, he was Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America. Ruud began his career as a scientist, researching in the field of immunology and ageing. He holds a doctorate in immunology from the University of Leiden in the Netherlands.

Paul Hudson

Mr. Paul Hudson is President, AstraZeneca, US and Executive Vice-President, North America., since January 2013 and leads AstraZeneca’s commercial operations in North America. In this capacity, he is accountable for driving growth and maximising the contribution of North America to AstraZeneca’s global business. Paul joined AstraZeneca in 2006 as Vice-President and Primary Care Director, UK and was later appointed President of AstraZeneca K. K., AstraZeneca’s Japanese subsidiary, and President of AstraZeneca’s business in Spain. He has served as a Standing Board Member of the Japan Pharmaceuticals Manufacturers Association and EFPIA in Japan. Before joining AstraZeneca, Paul worked for Schering-Plough, where he held senior global marketing roles. He received a degree in economics from Manchester Metropolitan University and a DipM from the UK’s Chartered Institute of Marketing.

Bahija Jallal

Dr. Bahija Jallal, Ph.D. is the Executive Vice President, MedImmune of AstraZeneca PLC., since January 2013 and is responsible for biologics research activities. Bahija is tasked with advancing the biologic pipeline of drugs. She joined MedImmune in 2006 as Vice-President, Translational Sciences and has held roles of increasing responsibility at AstraZeneca. Prior to joining AstraZeneca, Bahija worked with Chiron Corporation where she served as Vice-President, Drug Assessment and Development. Bahija received a master’s degree in biology from the Université de Paris VII and her doctorate in physiology from the Université Pierre et Marie Curie, Paris. She conducted her post-doctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany. She is a member of the American Association of Cancer Research, the American Association of Science, the Pharmacogenomics Working Group and the Board of Directors of the Association of Women in Science.

Mark Mallon

Mr. Mark Mallon is the Executive Vice President, International of AstraZeneca PLC., since January 2013 and is responsible for the growth and performance of AstraZeneca’s commercial businesses in various regions, including Asia Pacific, Russia, Latin America, the Middle East and Africa. Since joining AstraZeneca in 1994, Mark has held multiple senior sales and marketing roles, including Regional Vice-President for Asia Pacific, President of AstraZeneca’s Chinese and Italian subsidiaries, Chief Operating Officer of AstraZeneca’s Japanese subsidiary and VicePresident of AstraZeneca’s US gastrointestinal and respiratory businesses. He has served as a member of the Board of Directors for Christiana Care, the largest hospital system in Delaware, and an Executive Committee Member for R&D-based Pharmaceutical Association Committee, the China industry association for innovative pharmaceutical companies. Mark began his career in the pharmaceutical industry in management consulting. He holds a degree in chemical engineering from the University of Pennsylvania and an MBA in marketing and finance from the Wharton School of Business.

Luke Miels

Mr. Luke Miels is Executive Vice-President, Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs of the Company. Since May 2014 leading AstraZeneca’s global marketing and commercial operations. Luke began his career in 1995 with AstraZeneca in Australia as a Sales Representative and Product Manager for Plendil and Diprivan. He joined Aventis in 2000 as Marketing and Strategic Planning Manager in Australia and held roles of increasing seniority, from Country Manager for New Zealand and Thailand to leading the Analytics and Commercial Effectiveness function of Aventis US. Following the Sanofi-Aventis merger, he led the integration office in the US and was then appointed Vice-President of Sales for Metabolism. Luke joined Roche in 2006 as Head of Metabolism for Global Marketing and in 2009, was appointed Regional Vice-President Asia Pacific for the Pharmaceuticals Division, joining the Leadership Team of the Pharmaceuticals Division. Luke holds a BSc in biology from Flinders University in Adelaide and an MBA from the Macquarie University, Sydney.

Menelas Pangalos

Mr. Menelas Pangalos is the Executive Vice President - Innovative Medicines and Early Development of AstraZeneca PLC., since January 2013. He was appointed Executive Vice-President, IMED in January 2013 and leads AstraZeneca’s small molecule discovery research and early-stage development activities. Mene joined AstraZeneca from Pfizer, where he was Senior Vice-President and Chief Scientific Officer of Neuroscience Research. Previously, he held senior discovery and neuroscience roles at Wyeth and GSK. He completed his undergraduate degree in biochemistry at the Imperial College of Science and Technology, London and earned a doctorate in neurochemistry from the University of London. He is a Visiting Professor of Neuroscience at King’s College, London. In the UK, Mene serves on the Medical Research Council and the Innovation Board for the Association of the British Pharmaceutical Industry.

Katarina Ageborg

Ms. Katarina Ageborg is Chief Compliance Officer of AstraZeneca PLC. Katarina was appointed Chief Compliance Officer. Since July 2011 and has overall responsibility for the design, delivery and implementation of AstraZeneca’s compliance responsibilities. Since joining AstraZeneca in 1998, she has held various senior legal roles supporting Commercial and Regulatory and most recently led the Global IP function from 2008 to 2011. Before joining AstraZeneca, she established her own law firm in Sweden and worked as a lawyer practising on civil and criminal cases. Katarina holds a Master of Law from Uppsala University School of Law in Sweden.

Jeffrey Pott

Mr. Jeffrey Pott is General Counsel of AstraZeneca Plc., Since January 2009 and has overall responsibility for all aspects of AstraZeneca’s Legal and IP function. He joined AstraZeneca in 1995 and has worked in various litigation roles, where he has had responsibility for IP, anti-trust and product liability litigation. Before joining AstraZeneca, he spent five years at the US legal firm Drinker Biddle and Reath LLP, where he specialised in pharmaceutical product liability litigation and anti-trust advice and litigation. He received his bachelor’s degree in political science from Wheaton College and his Juris Doctor Degree from Villanova University School of Law.

Adrian Kemp

Tim Jackson-Smith

Mr. Tim Jackson-Smith is Non-Executive Director of the company. Since 2015. Tim has over 20 years' experience in legal practice in addition to significant, relevant experience in the listed-company environment, having served for more than eight years in both executive and non-executive director roles at a number of main market and AIM quoted companies.

Marcus Wallenberg

Mr. Marcus Wallenberg is the Non-Executive Director of AstraZeneca PLC., He was appointed as a Director in April 1999. Marcus Wallenberg has international business experience across a broad range of industry sectors, including the pharmaceutical industry from his directorship with Astra prior to 1999. He is the Chairman of Skandinaviska Enskilda Banken AB, AB Electrolux, Saab AB, LKAB and Foundation Asset Management AB. He is a member of the boards of Investor AB, Stora Enso Oyj, Temasek Holdings Limited, the Knut and Alice Wallenberg Foundation and EQT Holdings AB.

Genevieve Berger

Ms. Genevieve Berger is Non-Executive Independent Director of AstraZeneca Plc., effective April 26, 2012. She was Chief Science Officer at Unilever PLC and a member of the Unilever Leadership Executive from 2008 to April 2014. She holds three doctorates – in physics, human biology and medicine – and was appointed Professor of Medicine at Université Pierre et Marie Curie, Paris in 2006. Her previous positions include Professor and Hospital Practitioner at l’Hôpital de la Pitié-Salpêtrière, Paris; Director of the Biotech and Agri-Food Department, then Head of the Technology Directorate at the French Ministry of Research and Technology; Director General, Centre National de la Recherche Scientifique; and Chairman of the Health Advisory Board of the EU Commission.

Bruce Burlington

Dr. Bruce Burlington is Non-Executive Independent Director of AstraZeneca Plc. Bruce is a pharmaceutical product development and regulatory affairs consultant and brings experience in those areas to the Board. He is a pharmaceutical product development and regulatory affairs consultant and brings extensive experience in those areas. He spent 17 years with the FDA, serving as Director of its Center for Devices and Radiological Health as well as holding various senior roles in the Center for Drug Evaluation and Research. After leaving the FDA, he held various senior executive positions at Wyeth (now part of Pfizer). Other Appointments Bruce is a Non-Executive Director of the International Partnership for Microbicides, and a member of the scientific advisory boards of the International Medica Foundation and H. Lundbeck A/S.

Ann Cairns

Ms. Ann Cairns is Non-Executive Independent Director of the Company. She has more than 20 years’ in-depth financial and international business experience and currently serves as President, International Markets, for MasterCard. Before joining MasterCard in 2011, Ann oversaw the European liquidation of Lehman Brothers Holdings International and was the Chief Executive, Transaction Banking at ABN AMRO. At the start of her career, Ann was an award-winning research engineer, culminating as the head of Offshore Engineer – Planning for British Gas. She holds a BSc in pure mathematics from Sheffield University and an MSc with research into medical statistics from Newcastle University in the UK

Graham Chipchase

Mr. Graham Chipchase has been appointed as Non-Executive Independent Director of AstraZeneca PLC., effective April 26, 2012. He has served as Chief Executive Officer of global consumer packaging company, Rexam PLC (Rexam) since 2010 after serving at Rexam as Group Director, Plastic Packaging and Group Finance Director. Previously, he was Finance Director of Aerospace Services at the global engineering group GKN plc from 2001 to 2003. After starting his career with Coopers & Lybrand Deloitte, he held various finance roles in the industrial gases company The BOC Group plc (now part of The Linde Group). He is a Fellow of the Institute of Chartered Accountants in England and Wales and holds an MA (Hons) in chemistry from Oriel College, Oxford.

Jean-Philippe Courtois

Mr. Jean-Philippe Courtois is no longer as Non-Executive Independent Director of AstraZeneca Plc, effective 1 December 2016. Appointed as a Director in February 2008. He has more than 30 years’ experience in the global technology industry. He is President of Microsoft International and previously served as Chief Executive Officer and President of Microsoft EMEA. Jean-Philippe has also served as Co-Chairman of the World Economic Forum’s Global Digital Divide Initiative Task Force and on the European Commission Information and Communication Technology Task Force. In 2009, he served as an EU Ambassador for the Year of Creativity and Innovation and, in 2011, was named one of ‘Tech’s Top 25’ by The Wall Street Journal Europe.

Rudolph Markham

Mr. Rudolph Harold Peter Markham (Rudy) has been appointed as Senior Non-Executive Independent Director of AstraZeneca Plc. effective April 24, 2015. Rudy Markham takes a particular interest on behalf of the Board in SHE assurance. He has international business and financial experience, having formerly held a number of senior commercial and financial positions worldwide with Unilever, culminating in his appointment as Chief Financial Officer of Unilever. He is currently Chairman and Non- Executive Director of Moorfields Eye Hospital NHS Foundation Trust and a non-executive member of the boards of United Parcel Services Inc., Standard Chartered PLC and Legal & General plc. He is also a non-executive member of the board of the UK Foreign and Commonwealth Office, a member of the supervisory board of CSM NV, a Fellow of the Chartered Institute of Management Accountants and a Fellow of the Association of Corporate Treasurers. He served as a Non-Executive Director of the UK Financial Reporting Council from 2007 to 2012.

Shriti Vadera

Ms. Shriti Vadera is Non-Executive Independent Director of AstraZeneca PLC. She has significant knowledge of global finance, emerging markets and public policy. She has advised governments, banks and investors on the eurozone crisis, the banking sector, debt restructuring and markets and has served as a G20 Adviser and a Minister in the UK Cabinet Office and Business Department and International Development Department. She has also served on the Council of Economic Advisers, HM Treasury where she focused on business and international economic issues. Prior to that, Shriti spent 14 years in investment banking with SG Warburg/UBS. Other Appointments Shriti is Joint Deputy Chairman of Santander UK and has been a Non-Executive Director of BHP Billiton since 2011.

Thomas Larsen